



האיגוד הישראלי לכירורגית לב וחזה
THE ISRAEL SOCIETY OF CARDIOTHORACIC SURGERY

האיגוד הקרדיולוגי בישראל
ISRAEL HEART SOCIETY



The 60th International Conference of the Israel Heart Society in association with the Israel Society of Cardiothoracic Surgery

22-23 April 2013, ICC International Convention Center, Jerusalem

Differential impact of SSRIs on platelet response to clopidogrel: a randomized, double-blind, crossover trial.

Bruria Hirsh/Raccah, Galia Spectre, Ella Shai, Amit Lotan, Amit Ritter, David Varon and Ronny Alcalai.

, School of Pharmacy, coagulation unit, psychiatry department and the heart institute, Hadassah Hebrew University Medical Center



***The current presentation has no
conflict Of interest***

Introduction

- Selective serotonin reuptake inhibitors (SSRI) are antidepressant agents that are widely used
- SSRI block serotonin reuptake by platelets, causing platelet serotonin depletion and potentially impaired platelet function

Selective serotonin reuptake inhibitors and brain hemorrhage

A meta-analysis

Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction

Studies have shown that use of SSRI in combination with aspirin is associated with an increased risk bleeding

Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look

Lucie Opatrny,^{1,2} J. A. 'Chris' Delaney^{1,3} & Samy Suissa^{1,3}

¹Division of Clinical Epidemiology, ²Division of Internal Medicine, McGill University Health Center and ³Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada

Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study

Francisco José de Abajo, Luis Alberto García Rodríguez, Dolores Montero


CMAJ, November 8, 2011, 183(16)
Br J Clin Pharmacol / 66:1 / 76-81
BMJ Vol. 319 23 Oct. 1999
Neurology 1865-79:1862;2012

Introduction

- little information is known about the interaction of SSRIs and clopidogrel
- Clopidogrel is a pro-drug undergoing active metabolism in the liver by CYP2C19
- Fluvoxamine is an SSRI and inhibitor of CYP2C19
- Citalopram is an SSRI without known effect on liver metabolism

Introduction

Pharmacokinetic effect:
Inhibit CYP2C19 and
reduce response to
clopidogrel
fluvoxamine



Pharmacodynamic effect:
Inhibit platelet function and
potentially augment
response to clopidogrel
citalopram & fluvoxamine


Aim

To assess the effect of two different SSRIs on platelet aggregation and on the laboratory response to clopidogrel

Methods


- Randomized, double-blind, crossover study comparing the antiplatelet effects of clopidogrel with and without fluvoxamine and citalopram in 15 healthy volunteers
- Clopidogrel responsiveness was assessed by Light Transmittance Aggregometry (LTA) with $10\mu\text{mol/L}$ ADP and by vasodilator-stimulated phospho-protein (VASP) phosphorylation, a measure of P2Y₁₂ receptor reactivity.

Study design:



Results

Fluvoxamine and citalopram had modest effect on platelet reactivity at baseline





Results

Laboratory response to clopidogrel was significantly better in the presence of citalopram compare to fluvoxamine in both methods

LTA: $23.4\% \pm 3$ vs. $32.3\% \pm 4.2$

VASP: $35.9\% \pm 4.2$ vs. $52.7\% \pm 5.1$



Conclusions & Practical Implications:

- Fluvoxamine attenuate the laboratory response to clopidogrel, probably through inhibition of the CYP2C19, while citalopram does not affect this response
- Since SSRIs are commonly used in patients after coronary syndromes and interventions, clinicians should be aware of these drug interactions and guide the selection of the appropriate antidepressant agent according to its pharmacological properties and the cardiovascular risk.

